| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| May 13, 2016 | EBS Emergent Biosolutions Inc. | Sullivan Louis W62 | Director | Sell | 47,631 | $39.21 | $1,867,761.00 | -29.5% | |
| May 12, 2016 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 190,000 | $75.86 | $14,414,035.24 | - | |
| May 12, 2016 | LLY Eli Lilly & Co | Tai Jackson P | Director | Buy | 1,080 | $75.75 | $81,810.00 | +2.7% | |
| May 12, 2016 | AVDL Avadel Pharmaceuticals Plc | Anderson Michael S | Chief Executive Officer | Buy | 5,000 | $8.84 | $44,200.00 | +3.9% | |
| May 12, 2016 | EBS Emergent Biosolutions Inc. | Hauer Jerome M | Director | Sell | 4,700 | $38.50 | $180,950.00 | -25.0% | |
| May 12, 2016 | EBS Emergent Biosolutions Inc. | El-Hibri Fuad | Chairman | Sell | 25,000 | $38.71 | $967,750.00 | -1.5% | |
| May 12, 2016 | DVAX Dynavax Technologies Corp | Janssen Robert71 | Vice President | Buy | 1,000 | $15.12 | $15,120.00 | New | |
| May 12, 2016 | TLPH Talphera, Inc. | Edwards Mark G | Director | Buy | 15,000 | $3.15 | $47,250.00 | +4.8% | |
| May 11, 2016 | HYEX Healthy Extracts Inc. | Bossung William C | CFO And Secretary | Sell | 400,000 | $0.13 | $50,000.00 | -10.0% | |
| May 11, 2016 | NVS Novartis AG | Novartis Institutes For Biomedical Research, Inc. | 10% Owner | Buy | 277,777 | $18.00 | $4,999,986.00 | +5.2% | |
| May 11, 2016 | EBS Emergent Biosolutions Inc. | Sullivan Louis W62 | Director | Sell | 9,969 | $39.25 | $391,283.25 | -25.9% | |
| May 10, 2016 | MRK Merck & Co., Inc. | Holston Michael J | EVP, General Counsel | Sell | 100,021 | $54.50 | $5,451,144.50 | -60.9% | |
| May 10, 2016 | JNJ Johnson & Johnson | Kapusta Ronald A | Controller, CAO | Sell | 3,957 | $114.77 | $454,156.76 | -13.3% | |
| May 6, 2016 | AYTU Aytu Biopharma, Inc | Disbrow Jarrett | Chief Operating Officer | Buy | 250,000 | $0.40 | $100,000.00 | +162.5% | |
| May 6, 2016 | AYTU Aytu Biopharma, Inc | Disbrow Joshua R.57 | Chief Executive Officer | Buy | 250,000 | $0.40 | $100,000.00 | +162.5% | |
| May 6, 2016 | AYTU Aytu Biopharma, Inc | Dockery Carl | Director | Buy | 5,000,000 | $0.40 | $2,000,000.00 | +10,506% | |
| May 4, 2016 | ESPR Esperion Therapeutics, Inc. | Mayleben Timothy M | President &CEO | Buy | 7,000 | $14.85 | $103,950.00 | +20.2% | |
| May 2, 2016 | LLY Eli Lilly & Co | Zakrowski Donald A | Chief Accounting Officer | Sell | 1,600 | $75.86 | $121,368.00 | -22.1% | |
| Apr 29, 2016 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 180,000 | $75.44 | $13,580,051.86 | - | |
| Apr 27, 2016 | LLY Eli Lilly & Co | Zulueta Alfonso G | SVP&Pres., Emerging Markets | Sell | 12,000 | $76.27 | $915,240.00 | -21.0% | |
| Apr 22, 2016 | EBS Emergent Biosolutions Inc. | El-Hibri Fuad | Chairman | Sell | 4,209 | $40.50 | $170,464.50 | -0.2% | |
| Apr 19, 2016 | AMPH Amphastar Pharmaceuticals, Inc. | Gerst Diane G. | EVP, Qa &Regulatory Affairs | Sell | 21,244 | $12.89 | $273,774.10 | -26.1% | |
| Apr 18, 2016 | EBS Emergent Biosolutions Inc. | El-Hibri Fuad | Chairman | Sell | 20,791 | $40.50 | $842,035.50 | -1.2% | |
| Apr 18, 2016 | EBS Emergent Biosolutions Inc. | Abdun-Nabi Daniel | President &CEO | Sell | 8,702 | $40.17 | $349,559.34 | -1.5% | |
| Apr 15, 2016 | PCRX Pacira Biosciences, Inc. | Stack David M67 | CEO And Chairman | Sell | 25,000 | $64.14 | $1,603,377.50 | -78.3% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.